BR122019014196B8 - derivados do ácido 4- ou 5-aminossalicílico, e composição farmacêutica - Google Patents

derivados do ácido 4- ou 5-aminossalicílico, e composição farmacêutica

Info

Publication number
BR122019014196B8
BR122019014196B8 BR122019014196A BR122019014196A BR122019014196B8 BR 122019014196 B8 BR122019014196 B8 BR 122019014196B8 BR 122019014196 A BR122019014196 A BR 122019014196A BR 122019014196 A BR122019014196 A BR 122019014196A BR 122019014196 B8 BR122019014196 B8 BR 122019014196B8
Authority
BR
Brazil
Prior art keywords
aminosalicylic acid
treatment
pharmaceutical composition
derivatives
acid derivatives
Prior art date
Application number
BR122019014196A
Other languages
English (en)
Portuguese (pt)
Other versions
BR122019014196B1 (pt
Inventor
Sparatore Anna
Caliendo Giuseppe
Cirino Giuseppe
L Wallace John
Fiorucci Stefano
Santagada Vincenzo
Original Assignee
Antibe Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antibe Holdings Inc filed Critical Antibe Holdings Inc
Publication of BR122019014196B1 publication Critical patent/BR122019014196B1/pt
Publication of BR122019014196B8 publication Critical patent/BR122019014196B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6578—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and sulfur atoms with or without oxygen atoms, as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6587—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having two phosphorus atoms as ring hetero atoms in the same ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
BR122019014196A 2005-05-27 2006-03-31 derivados do ácido 4- ou 5-aminossalicílico, e composição farmacêutica BR122019014196B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CA2005/000819 WO2006125293A1 (en) 2005-05-27 2005-05-27 Derivatives of 4- or 5-aminosalicylic acid
CAPCT/CA2005/000819 2005-05-27
PCT/CA2006/000484 WO2006125295A1 (en) 2005-05-27 2006-03-31 Derivatives of 4-or 5-aminosalicylic acid
BRPI0605840-0A BRPI0605840A (pt) 2005-05-27 2006-03-31 derivados do ácido 4- ou 5-aminossalicìlico

Publications (2)

Publication Number Publication Date
BR122019014196B1 BR122019014196B1 (pt) 2020-02-11
BR122019014196B8 true BR122019014196B8 (pt) 2021-07-27

Family

ID=37451592

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122019014196A BR122019014196B8 (pt) 2005-05-27 2006-03-31 derivados do ácido 4- ou 5-aminossalicílico, e composição farmacêutica
BR122019014203A BR122019014203B8 (pt) 2005-05-27 2006-03-31 derivados do ácido 4- ou 5-aminossalicílico, e composição farmacêutica
BRPI0605840-0A BRPI0605840A (pt) 2005-05-27 2006-03-31 derivados do ácido 4- ou 5-aminossalicìlico

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122019014203A BR122019014203B8 (pt) 2005-05-27 2006-03-31 derivados do ácido 4- ou 5-aminossalicílico, e composição farmacêutica
BRPI0605840-0A BRPI0605840A (pt) 2005-05-27 2006-03-31 derivados do ácido 4- ou 5-aminossalicìlico

Country Status (17)

Country Link
US (1) US7910568B2 (https=)
EP (1) EP1883645B1 (https=)
JP (1) JP5221341B2 (https=)
KR (1) KR101298880B1 (https=)
CN (1) CN101238137B (https=)
AT (1) ATE514704T1 (https=)
AU (1) AU2006251803B2 (https=)
BR (3) BR122019014196B8 (https=)
CA (1) CA2609224C (https=)
ES (1) ES2368650T3 (https=)
IL (1) IL187319A (https=)
NO (1) NO340528B1 (https=)
NZ (1) NZ563354A (https=)
RU (1) RU2414476C2 (https=)
UA (1) UA96264C2 (https=)
WO (2) WO2006125293A1 (https=)
ZA (1) ZA200710472B (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741359B2 (en) 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
DK2057139T3 (da) 2006-07-18 2013-11-18 Antibe Holdings Inc Hydrogensulfidderivater af non-steroide anti-inflammatoriske lægemidler
UA102216C2 (ru) * 2006-07-18 2013-06-25 Антиб Терапьютикс Инк. 4-гидрокситиобензамидные производной лекарственных веществ
CN101680086B (zh) * 2007-05-21 2012-05-23 乔治洛德方法研究和开发液化空气有限公司 用于半导体领域的新型金属前体
CN101541780B (zh) * 2007-06-08 2012-12-05 成都地奥九泓制药厂 贝特羧酸酯类化合物及其制备方法和用途
EP2062578A1 (en) * 2007-11-12 2009-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel use of chemical compounds for the treatment of AIDS
ITMI20072429A1 (it) * 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
EP2744487B1 (en) 2011-08-15 2016-10-05 Research Foundation Of The City University Of New York No- and h2s- releasing compounds
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
CN102807557B (zh) * 2012-08-21 2015-02-04 苏州大学 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
CA2905435A1 (en) * 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN103254257A (zh) * 2013-04-18 2013-08-21 山西医科大学 一种4-氨基水杨酸糖苷类衍生物及其制备方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
CN103483214B (zh) * 2013-06-09 2015-04-29 西安交通大学 一种化合物及其制备方法和抗溃疡性结肠炎用途
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109640965A (zh) 2016-08-11 2019-04-16 塞尔利克斯生物私人有限公司 用于治疗肠易激综合征的组合物和方法
WO2019008441A1 (en) * 2017-07-04 2019-01-10 Intocell, Inc. COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF
US10100005B1 (en) * 2017-11-17 2018-10-16 Eclipse Therapeutics, LLC Mesalazine derivatives
KR20220055697A (ko) 2020-10-27 2022-05-04 강원대학교산학협력단 살리신을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CN113398112A (zh) * 2021-06-17 2021-09-17 西南医科大学 FA介导的BBA/CM-β-CD靶向递药系统、制备方法及其应用
CN115960075B (zh) * 2021-10-08 2024-11-08 深圳枫语生物医药科技有限公司 一种咖啡酸衍生物及其制备方法和应用
CN114605277B (zh) * 2022-04-18 2022-10-11 宁波怡和医药科技有限公司 一种美沙拉嗪的合成方法
CN116444408B (zh) * 2023-06-14 2023-09-26 山东大学 一种多靶点型双硫仑衍生物、药物组合物及其抗肿瘤应用
CN117679402A (zh) * 2024-01-10 2024-03-12 北京化工大学 莱菔素在制备治疗溃疡性结肠炎药物中的应用
WO2025248450A1 (en) * 2024-05-28 2025-12-04 Antibe Therapeutics, Inc. H2s-releasing mesalamine analogs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE900937C (de) * 1952-05-14 1954-01-04 Dr Bruno Boettcher Verfahren zur Herstellung schwefelhaltiger organischer Verbindungen
BE642496A (https=) 1963-01-16 1964-07-01
US4161550A (en) * 1977-09-21 1979-07-17 The Procter & Gamble Company Meat aroma precursor composition
JPS57500432A (https=) 1980-03-20 1982-03-11
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
JPH04154773A (ja) * 1990-10-15 1992-05-27 Green Cross Corp:The チアゾール誘導体
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
CA2204747C (en) * 1995-09-08 2009-05-05 Elena Carceller New azo derivatives of 5-aminosalicylic acid
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
IT1311923B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
AU2001285489A1 (en) * 2000-08-29 2002-03-13 Nobex Corporation 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
EP1645288A1 (en) 2004-10-07 2006-04-12 CTG Pharma S.r.l. New nuclear transcription factors regulators
EP1836160A1 (en) 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid

Also Published As

Publication number Publication date
CA2609224A1 (en) 2006-11-30
IL187319A0 (en) 2008-04-13
UA96264C2 (ru) 2011-10-25
JP2008542209A (ja) 2008-11-27
IL187319A (en) 2013-10-31
ATE514704T1 (de) 2011-07-15
EP1883645A4 (en) 2008-06-25
JP5221341B2 (ja) 2013-06-26
WO2006125293A1 (en) 2006-11-30
KR101298880B1 (ko) 2013-08-21
NO340528B1 (no) 2017-05-02
CN101238137A (zh) 2008-08-06
BR122019014203B8 (pt) 2021-07-27
KR20080031216A (ko) 2008-04-08
CN101238137B (zh) 2012-05-02
WO2006125295A1 (en) 2006-11-30
US20080207564A1 (en) 2008-08-28
AU2006251803A1 (en) 2006-11-30
ZA200710472B (en) 2009-08-26
RU2414476C2 (ru) 2011-03-20
EP1883645B1 (en) 2011-06-29
ES2368650T3 (es) 2011-11-21
HK1121163A1 (en) 2009-04-17
EP1883645A1 (en) 2008-02-06
BR122019014203B1 (pt) 2020-02-11
CA2609224C (en) 2014-04-29
BRPI0605840A (pt) 2007-12-18
NO20076625L (no) 2008-02-26
RU2007148924A (ru) 2009-07-10
US7910568B2 (en) 2011-03-22
AU2006251803A8 (en) 2006-11-30
BR122019014196B1 (pt) 2020-02-11
AU2006251803B2 (en) 2012-05-24
NZ563354A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
BR122019014203B8 (pt) derivados do ácido 4- ou 5-aminossalicílico, e composição farmacêutica
Dubey et al. Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
EP2240464A4 (en) PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE PRODUCTS
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
CN105764909B (zh) 用于治疗泛酸激酶相关神经变性(pkan)的稳定泛酰巯基乙胺衍生物及用于合成这样的化合物的方法
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
WO2008075366A2 (en) Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
Pitcher et al. Development of 1, 2, 4-oxadiazole antimicrobial agents to treat enteric pathogens within the gastrointestinal tract
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2077719A4 (en) PIPERIDINE AND PYRROLIDIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
ATE483679T1 (de) Substituierte cyclohexylessigsäure-derivate
EA200800421A1 (ru) Соединения
EA201390615A1 (ru) Производные дитерпеноидов, обладающие биологическими свойствами
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
ATE471318T1 (de) Neue indol-pyrrol-derivate zur behandlung proliferativer und inflammatorischer krankheiten
WO2007019888A3 (en) Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
EA200702036A1 (ru) Применение макролидов для лечения флегмоны кишечника
JP2009179602A (ja) エレウテリノシドａ、ｂ、ｃ
ATE317380T1 (de) Bernsteinsäurederivate
NAORUNGROJ Antimicrobial and Antibiofilm Activities of Synthetic Lawsone Derivatives Containing N-Substituted 1, 2, 3-Triazole Against Dental Caries Pathogens

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07F 9/6578 , C07D 339/04 , C07C 333/02 , C07C 327/40 , C07C 321/14 , A61K 31/16 , A61K 31/27 , A61K 31/255 , A61K 31/325

Ipc: C07C 327/48 (1990.01), C07C 333/02 (1990.01), C07C

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO